NCT07149064

Effect of Chronic Exposure to Nextida GC-B on Glycemic Control in Adults With Normoglycemia or Prediabetes

A Randomized, Triple-blind, Placebo Controlled, Parallel Clinical Trial to Investigate the Efficacy and Safety of Chronic Exposure to Nextida GC-B on Glycemic Control in Adults With Normoglycemia or Prediabetes

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Rousselot BVBA · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The goal of this clinical trial is to investigate the safety and efficacy of Nextida GC-B on glycemic control in adults with normoglycemia and prediabetes. The main question it aims to answer is: What is the difference in change in postprandial glycemic control from baseline at Day 90 between Nextida GC-B and placebo as assessed by glucose incremental AUC (iAUC 0-180 min).

Conditions

• Normoglycemia
• Prediabetes
• Glycemic Control

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Nextida GC-B	One liquid shot contains 5 g of collagen hydrolysate.
OTHER	Placebo	One liquid shot contains non-active ingredients in Nextida GC-B (water, Erythritol, Citric Acid, DL-Malic Acid, Natural Apples Flavor, Steviol Glycosides).

Timeline

• Start date: 2026-02-18
• Primary completion: 2026-08-01
• Completion: 2026-08-01
• First posted: 2025-08-29
• Last updated: 2026-03-16

Locations

1 site across 1 country: Canada